Advancing Global Tourism Industry Trade: Tourism Plus Shanghai 2026 Calls for Worldwide Exhibitors
Tourism Plus Shanghai (TPS 2026) is guided by Shanghai Municipal Administration of Culture and Tourism, co-sponsored by China Tourism Association, and hosted by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd. and Shanghai International Convention & Exhibition Co., Ltd. The expo accelerates the deep integration of "tourism + industries" and "industries + tourism", catalyzing innovation in hospitality, retail, sports, and related sectors. It fosters emerging business models and establishes a new framework for global tourism industry development. Suppliers of tourism services, catering supply chain, hotel supplies, retail technology and equipment, boat and outdoor products, and entertainment projects will present their latest products and services to international buyers.
Concurrently, TPS 2026 provides a strategic platform for overseas destinations to access the Chinese market and facilitates partnerships with Chinese investors and trade entities. Through targeted matchmaking conferences and digital tools, the event bridges global supply chains with demand-driven opportunities.
Three Major Venues in Shanghai Host 42 Exhibition Categories
March 29 th -31 st, 2026
Shanghai World Expo Exhibition & Convention Center ： Tourist Destinations & Road trip route | Tourism & Cultural Technology | Tourism Operation & Facilities | Tourism & Cultural Consumption | Outdoor Sports | Health Plus | Boat | Boat Equipment and Accessories | Boat Service | Water sports | BBDS | Lure Fishing l Design company | Manufacturing factory | Internet-famous Prop | Light-based Art Display
March 30 th - April 2 nd, 2026
National Exhibition and Convention Center (Shanghai) ： Catering Equipment & Supplies | Central Kitchen Equipment & Food Machinery and Equipment | Refrigeration Equipment | Tableware | Finefood | Beverage | Coffee &Tea | Ice Cream & Dairy | Baking Equipment & Raw Materials | Food & Catering Packaging | The Bar & Drinks | Brand Franchising & Chain Store Resources
March 31 st - April 3 rd, 2026
Shanghai New International Expo Center ：Hotel Supplies | Smart Hotel | Hotel Franchise | Building & Decoration | Engineering Design | Lighting | Commercial Retail | Smart Office | Landscape Gardens | Hotel Furniture | Sunshading Material | Cleaning Operation & Maintenance | Property Management | Urban Appearance & Environmental Sanitation
From March 29th-April 3rd, 2026, we hope to see you in Shanghai, China.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
an hour ago
- Korea Herald
LG Display presents world's best OLED technologies alongside historic firsts at K-Display 2025
SEOUL, South Korea, Aug. 7, 2025 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today its participation in K-Display 2025 at COEX in Seoul for three days from Aug. 7, as the company is showcasing innovative technologies and products ranging from large, medium, and small-sized panels to automotive displays. LG Display is presenting OLED innovations and display solutions that bridge the present and future under the theme, "Shaping the Future." In particular, the exhibition features an experience Zone where visitors can directly encounter the world's first and best technologies, enhancing their understanding of LG Display's capabilities. The OLED Heritage exhibition space allows visitors to see at a glance the technological leadership LG Display has achieved since becoming the first in the world to successfully mass-produce large-sized OLED panels. This journey covers the company's 15-inch OLED panel prototype from 2009, which laid the foundation for OLED TV panels, as well as a Tandem OLED panel with a two-layer structure, the deuterium atom structure of second-generation OLED, the Micro Lens Array (MLA) technology of third-generation OLED, and the Primary RGB Tandem structure of fourth-generation OLED. All are presented so that visitors can more intuitively understand OLED technology. At the booth's entrance, visitors witness LG Display's 83-inch OLED panel featuring fourth-generation OLED technology, which was newly unveiled by the company this year. Fourth-generation OLED achieves a maximum brightness of 4,000 nits based on the industry's first Primary RGB Tandem technology, which stacks the three primary colors of light (red, green, and blue) as independent layers. LG Display is demonstrating a comparison of the previous generation's picture quality with that of fourth-generation OLED panels using ultra-large-sized panels, highlighting the incredible three-dimensionality and rich color reproduction of its latest technology. In addition, it is unveiling the world's fastest OLED monitor panel for the first time. LG Display's 540Hz 27-inch OLED panel (QHD) applies Dynamic Frequency & Resolution (DFR) technology to achieve an ultra-high refresh rate of up to 720Hz (HD) depending on the user's needs. Combined with fourth-generation OLED technology, it boasts the highest level of picture quality among OLED monitor panels, with 99.5% DCI-P3 color reproduction and a maximum brightness of 1,500 nits. Also on show is a 45-inch 5K2K (5120×2160) OLED panel, which boasts the world's highest resolution among existing OLED monitor panels. Visitors are able to play games using this panel and thereby discover the difference refresh rates make to gaming. Those in attendance additionally have the chance to experience LG Display's various automotive display technologies and products in an auto cockpit with a living space concept that facilitates fully autonomous mobility beyond software-defined vehicles (SDVs). The 57-inch Pillar-to-Pillar LCD at the center of the cockpit is the largest automotive display currently available, providing information and entertainment functions as desired through its natural curved screen. There is also a 32.6-inch Slidable OLED for vehicles, which unfolds downward when needed, as well as an ultra-bright 29-inch Outdoor LCD, which can be used for both advertising and communication with the world outside the vehicle. Moreover, LG Display is exhibiting a 47.8-inch LTPS LCD equipped with Switchable Privacy Mode (SPM) technology, allowing the screen in front of the passenger seat to be adjusted so that it is not visible from the driver's seat. The company is also introducing the world's first jog dial for vehicles that utilizes a Stretchable display that can stretch up to 53%. This innovative product maintains a smooth and flat form when not in use, but when a button is touched, it stretches to form a jog dial. Additionally, there is a 14-inch Tandem ATO featuring LG Display's Tandem structure for the first time in the industry, offering both high brightness with low power consumption while also enabling a thin and lightweight design with a single glass substrate structure. A 14.5-inch LCD unveiled alongside it uses advanced Oxide TFT and low-power backlight technology to maximize battery life, providing an optimized display solution for the AI era's significantly higher power consumption. "The LG Display-led technological evolution of OLED is changing the paradigm of displays," said an official at LG Display. The official added, "We will secure sustainable technological competitiveness and provide differentiated customer value by not only bringing commercial technologies to maturity but also solidly preparing R&D capabilities for future technologies." About LG Display LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world's leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays. The company manufactures display panels in a broad range of sizes and specifications primarily for use in TVs, notebook computers, desktop monitors, automobiles, and various other applications, including tablets and mobile devices. LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam
Korea Herald
an hour ago
- Korea Herald
Luxury Jeweler, Chow Sang Sang, Selects Nuvei to Power Online Payments and Accelerate Global Expansion
Iconic brand joins growing roster of Nuvei merchants scaling globally from Hong Kong MONTREAL, Aug. 6, 2025 /PRNewswire/ -- Nuvei today announced that Chow Sang Sang Holdings International Limited (HKEX: 116), one of the most iconic jewelers in Greater China, has selected its global payments platform to drive the next phase of its international growth, staring with expansion into North America. Nuvei recently received a Money Services Operator (MSO) license in Hong Kong, enabling the company to offer local acquiring and settlement in one of Asia's most strategically important markets. It also reinforces Nuvei's long-term commitment to the APAC region, where it continues to expand its on-the-ground presence across Greater China, Japan, Singapore, and Australia. As Chow Sang Sang accelerates its digital payments transformation, Nuvei will deliver seamless, secure, and fully localized payment experiences to support the brand's international growth. Through a single integration with Nuvei's platform, the jeweler gains access to: "As we expand internationally, especially into North America, we needed a payments partner who shares our dedication to excellence," added Ms. Genevieve Chow, Chief Brands Officer at Chow Sang Sang."Nuvei's platform, local knowledge, and global reach enable us to deliver the premium experience our customers expect, online and in-store. This partnership is a key part of our omnichannel strategy." This announcement comes amid a boom in digital luxury. Global online jewelry sales are projected to rise from $105.6 billion in 2024 to $166 billion by 2029, a 16% CAGR. In the U.S. alone, ecommerce sales of jewelry are projected to rise from $22.5 billion to $37.9 billion over the same period – more than tripling since 2017[1]. "Luxury brands like Chow Sang Sang are raising the bar for global ecommerce," said Phil Fayer, Chair and CEO of Nuvei. "They require partners who can deliver intelligent infrastructure that matches their brand sophistication. With our MSO license and expanding APAC footprint, we're proud to support the region's most ambitious companies with payments technology built for scale." Chow Sang Sang, which operates over 900 self-run stores across Mainland China, the Hong Kong Region, the Macau Region, and the Taiwan Region, brings to market a portfolio of beloved brands, including CHOW SANG SANG, PROMESSA, MINTYGREEN, and EMPHASIS. The jeweler joins a growing list of Hong Kong-based merchants across verticals — including airlines, hospitality, gaming, online travel, car parking, and EV charging — that have recently chosen Nuvei to scale their global operations. Nuvei already supports APAC expansion for category leaders such as Shein, Temu, and Charles & Keith. About Nuvei Nuvei is accelerating the business of clients around the world. Nuvei's modular, flexible and scalable technology allows leading companies to accept next-gen payments, offer all payout options and benefit from card issuing, banking, risk and fraud management services. Connecting businesses to their customers in more than 200 markets, with local acquiring in 50 markets, 150 currencies and 720 alternative payment methods, Nuvei provides the technology and insights for customers and partners to succeed locally and globally with one integration.
Korea Herald
an hour ago
- Korea Herald
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of AVTOZMA ® (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older. Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA ® IV in the United States. [1] Earlier this year, the FDA approved AVTOZMA as a biosimilar to ACTEMRA in IV formulations for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19). [1] CRS is a potentially life-threatening condition that occurs when the immune system is highly activated, leading to the rapid and excessive release of cytokines into the bloodstream. During a cytokine storm, the overactivated immune system can cause widespread inflammation and damage to healthy tissue and organs throughout the body with symptoms ranging from mild, flu-like symptoms to more severe complications such as low blood pressure, difficulty breathing, and multi-organ failure. [2] "We are proud that AVTOZMA IV has now achieved full indication alignment with the reference ACTEMRA IV. This milestone marks an important step forward in our mission to deliver a safe and effective therapy for CRS," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "This FDA approval expands access to high-quality biologics and supports beneficial patient outcomes across multiple therapeutic areas." In accordance with the patent settlement agreement with Genentech, the IV formulation of AVTOZMA is expected to be available in the U.S. on August 31, 2025. Celltrion holds a license to market the subcutaneous formulation in the U.S. commencing on the licensed launch date, which remains confidential. Notes to Editors: AVTOZMA ® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab. AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. INDICATION AVTOZMA ® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS INFECTIONS AVTOZMA ® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants. If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include: Monitor patients for signs of infection, including TB, during and after AVTOZMA treatment. Contraindications: Known hypersensitivity to tocilizumab products. Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled. Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management. Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop. Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts. Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant. Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity. Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders. Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended. Live Vaccines. Avoid concurrent use with AVTOZMA. Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions. About Celltrion Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 countries. Celltrion has seven biosimilars approved by the U.S. FDA: INFLECTRA ® (infliximab-dyyb), TRUXIMA ® (rituximab-abbs), HERZUMA ® (trastuzumab-pkrb), VEGZELMA ® (bevacizumab-adcd), YUFLYMA ® (adalimumab-aaty), STEQEYMA ® (ustekinumab-stba), and AVTOZMA ® (tocilizumab-anoh), as well as novel biologic ZYMFENTRA ® (infliximab-dyyb). For more information, please visit Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", "anticipates", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.
